Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR100DP1 in Mild to Moderate Atopic Dermatitis
NCT07914088Phase 2Recruiting
- Sponsor
- ARJIL Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing 0.5% AR100DP1 with Placebo (2 arms). Primary endpoint: Change of Investigator's Global Assessment to 0 or 1 at 14 days. Started Oct 2026; status: recruiting.
02
Drugs
ovatodiolide
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07914088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07914088.